Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective-Reference-Cited by-同舟云学术

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective

Published:2018-06 Issue:6 Volume:18 Page:375-379
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Saglio Giuseppe,Sharf Giora,Almeida Antonio^ORCID,Bogdanovic Andrija,Bombaci Felice,Čugurović Jelena,Deekes Nigel,Garcia-Gutiérrez Valentín,de Jong Jan,Narbutas Šarūnas,Westerweel Peter,Zackova Daniela

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries;Hoffman;Leukaemia,2015

2. The concept of treatment-free remission in chronic myeloid leukemia;Saußele;Leukaemia,2016

3. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?;Goldman;Leuk Lymphoma,2006

4. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia;Radich;Hematol Oncol Clin North Am,2017

5. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study;Hochhaus;Leukemia,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF;Leukemia;2024-03-12

2. The potential of circHIPK3 as a biomarker in chronic myeloid leukemia;Frontiers in Oncology;2024-03-05

3. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel;Blood Advances;2021-11-24

4. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts;Frontiers in Pharmacology;2021-06-30

5. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study;Cancer Medicine;2021-02-16